Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline BRCA1 / 2 -Mutated Breast Cancers in the High-Risk, Early-Stage Setting.
JCO precision oncology（2023）
摘要
Clinical trial results demonstrate the pronounced clinical benefits of pembrolizumab combined with chemotherapy for high-risk, early-stage TNBC and adjuvant olaparib for high-risk, early-stage HER2-negative /-mutated breast cancer.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要